Zecotek Photonics Inc.

Zecotek Photonics Inc.

March 26, 2010 17:40 ET

Zecotek Initiates Program to Improve Market Liquidity

SINGAPORE, SINGAPORE--(Marketwire - March 26, 2010) - Zecotek Photonics Inc. (TSX VENTURE:ZMS)(FRANKFURT:W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that it is initiating a Market Liquidity Program (more commonly known as market-making) managed by the Calgary office of CHF Investor Relations, its investor relations firm.

Further to the Company's previous announcement regarding the engagement of CHF's services (dated August 7, 2009), Zecotek Holdings Inc., a significant shareholder that is controlled by Zecotek's Chairman and CEO, Dr. A. F. Zerrouk, has furnished share capital for the purposes of market-making. The market-making activity will be conducted using a registered broker, in compliance with the guidelines established by the TSX Venture Exchange Policy 3.4 and other relevant policies, so that trading orders in Zecotek's shares are made to manage volatility and improve liquidity. 

About CHF Investor Relations

CHF's is an outsourced, low-cost equivalent to an internal investor relations department for its client companies. CHF serves an international portfolio of TSX/TSX Venture listed companies and others that may seek to list on North American Exchanges that operate in a broad range of industries including high-tech, mining exploration and producers, oil & gas, industrial and business solutions and products, and "green" companies. The depth of capital market experience is formidable dating back to the late 1970's. CHF's head office is in Toronto with another Canadian office in Calgary as well as branch offices in New York, USA; São Paulo, Brazil; and Shanghai, China.

If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada (IIROC) accepts responsibility for the adequacy or accuracy of this release.

Contact Information